EGFR and non-small cell lung carcinoma: Preclinical models of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells showed that the concomitant inhibition of both SMO and MET led to significant antiproliferative and proapoptotic effects, as well as the loss of the mesenchymal phenotype, suggesting new combination strategies [154].